Management of factor Xa inhibitor–related traumatic non‐intracranial bleeding events with andexanet alfa or four‐factor prothrombin complex concentrate in a US multicenter observational study
This analysis provides insights into the clinical characteristics and management strategies, including time to treatment, for patients treated with andexanet alfa or 4F-PCC while hospitalized for FXa inhibitor-related traumatic bleeds.
Authors
- Paul P. Dobesh (ORCID: https://orcid.org/0000-0002-2668-7168)
- Mark D. Danese (ORCID: https://orcid.org/0000-0002-7068-9603)
- Eva Lesén (ORCID: https://orcid.org/0000-0002-2198-4382)
- Craig I Coleman (ORCID: https://orcid.org/0000-0003-4868-7158)
- Raymond Chuen‐Chung Chang (ORCID: https://orcid.org/0000-0001-8538-7993)
- Gregory J. Fermann (ORCID: https://orcid.org/0000-0002-6264-8545)
- Onivefu E. Odelade
Institutions
- AstraZeneca (United Kingdom) (GB)
- Hartford Hospital (US)
- Nebraska Medical Center (US)
- University of Connecticut (US)
- Clinical Insights (US)
- AstraZeneca (Sweden) (SE)
- AstraZeneca (United States) (US)
- Hartford Financial Services (United States)
- University of Nebraska Medical Center (US)
- University of Cincinnati (US)
Publication Details
- Journal
- Journal of the American College of Emergency Physicians Open
- Published
- 2024-11-08
- DOI
- https://doi.org/10.1002/emp2.13333
- Citations
- 1
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.40
Funders
- AstraZeneca
- Alexion Pharmaceuticals